

## **RegenoMac:** A novel treatment for blindness due to retinal diseases



#### **Dr Cormac Flynn**

Founder and CEO

European Union

European Regional

OLLSCOLD GAILLIMHE UNIVERSITY OF GALWAY

IRELAND

DUFFY

December 2023



# "I'd rather lose my arm than lose my vision"



Diabetic macular oedema (DME) is the leading cause of blindness in the developed world






uropean Unio

European Regiona



### **Current Standard of Care Limitations**





## **RegenoMac**

**Repurposed API** modified for suitability in ocular conditions

**Directly targets persistent fluid** to dry the retina where existing drugs cannot

Utilises existing patient pathway


Safety study completed in a rabbit model

IP being filed November 2023

Market penetration TAM \$4Bn SOM \$500M

Clinician feedback

"It doesn't matter how you dry the retina, as long as you dry it, the vision will improve"







#### **Core Team**



Dr Cormac Flynn CEO Engineer w/PhD in biomaterials Prior: BioInnovate Operations manager CDMO R&D engineer

Dr Vijay Kumar Senior Scientist Pharmacist PhD in nanomaterials

Ms Catriona Dunleavy Director / Legal Solicitor Specialties: Contracts M&A Negotiation



Dr Joanne O'Dwyer Technical Lead Pharmacist PhD in drug delivery

Ms Deirdre Townley Clinical Advisor Consultant Ophthalmologist Specialising in Diabetic Retinopathy Member of EU Board of Ophthalmology


Prof Garry Duffy Scientific Advisor Professor of Anatomy Hydrogel formulation 2 x Founder







#### **Key Milestones**



DLLSCOIL N GAILLIMHE





• Novel therapy to restore vision in patients with DME than have no alternative



European Regiona

- The right team is in place and €2M is required to complete the pre-clinical phase and €8M for the phase 1 study
- With positive Phase 2 data in 2029, very attractive to partnerships or acquisition